Pfizer Secures Exclusive Rights to YaoPharma's Oral GLP-1 Agonist YP05002 in $2.1 Billion Deal
核心洞察
Pfizer has entered an exclusive global collaboration with YaoPharma (搜索) for YP05002 (搜索), a small molecule GLP-1 receptor (搜索) agonist currently in Phase 1 development for chronic weight management.
The agreement includes a $150 million upfront payment and potential milestone payments up to $1.935 billion, plus tiered royalties on sales if approved.
Pfizer plans to conduct combination studies of YP05002 (搜索) with its GIPR (搜索) antagonist PF-07976016, currently in Phase 2 development.
Pfizer Inc. has secured exclusive global rights to develop and commercialize YP05002 (搜索), an oral small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist from YaoPharma (搜索), in a collaboration agreement worth up to $2.085 billion. The deal announced December 9, 2025, strengthens Pfizer's cardiometabolic portfolio as the company positions itself in the rapidly expanding obesity (搜索) treatment market.
Strategic Partnership Details
Under the agreement terms, YaoPharma (搜索) will receive $150 million upfront and is eligible for milestone payments up to $1.935 billion tied to development, regulatory, and commercial achievements, plus tiered royalties on future sales. YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical Group (搜索), will complete the ongoing Phase 1 clinical trial before transferring development responsibilities to Pfizer.
"We look forward to contributing our expertise and resources to continue the development of this investigational GLP-1 small molecule which complements and strengthens our growing portfolio of novel candidates for treating obesity (搜索) and its adjacent diseases," said Chris Boshoff, M.D., Ph.D., Chief Scientific Officer and President, Research & Development at Pfizer. "Cardiometabolic research is a strategic priority for Pfizer that has the potential to be a key driver of growth for our business."
Oral Delivery Advantage
YP05002 (搜索) represents a potential advancement in GLP-1 therapy delivery, offering an oral alternative to the injectable formulations currently dominating the market. YaoPharma (搜索) independently developed the small-molecule compound with proprietary intellectual property rights, targeting multiple metabolic conditions including chronic weight management, type 2 diabetes (搜索), and metabolic dysfunction-associated steatohepatitis (搜索).
"The partnership with Pfizer marks the international recognition of Yao pharma's R&D capabilities," stated Liu Qiang, chairman of YaoPharma (搜索). "Leveraging Pfizer's exceptional global development experience and commercialization network, along with Yao Pharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to enable this innovative drug candidate to be developed and commercialized in order to benefit patients worldwide more quickly and broadly."
Combination Therapy Strategy
Pfizer plans to explore combination studies pairing YP05002 (搜索) with PF-07976016, its glucose-dependent insulinotropic polypeptide receptor (GIPR (搜索)) antagonist currently in Phase 2 development. This dual-pathway approach could potentially enhance therapeutic efficacy for obesity (搜索) and related metabolic disorders.
The collaboration also extends to other small molecules in Pfizer's pipeline, suggesting a comprehensive strategy to develop multi-target therapies for cardiometabolic diseases.
Market Positioning
Chen Yuqing, chairman of Fosun Pharma, emphasized the strategic importance of the partnership: "The global collaboration with Pfizer is another significant milestone in Fosun Pharma's strategy of innovation and internationalization. Fosun Pharma is committed to addressing unmet clinical needs. We look forward to working with Pfizer to expedite the global development and commercialization of YP05002 (搜索), with the goal of working toward addressing the challenges of obesity (搜索) and metabolic diseases for patients in need."
The agreement positions Pfizer to compete more effectively in the cardiometabolic space, where oral delivery could offer significant patient convenience advantages over current injectable therapies. YaoPharma (搜索) retains responsibility for completing the ongoing Phase 1 trial, after which Pfizer will assume full development and commercialization rights worldwide.